Katina Dorton
Independent DirectorMs. Katina Dorton, J.D. MBA, is Independent Director of Prelude Therapeutics Incorporated since October 17, 2025 and Mallinckrodt plc from February 2024. She serves as Director at Sonoma Biotherapeutics, Inc. since August 2022. She is an experienced financial executive, corporate director and Chief Financial Officer. She serves as Independent Director at TScan Therapeutics, Inc. since March 2021. Ms. Dorton served as Chief Financial Officer of Nodthera Limited since December 2020. She serves as a Member of Advisory Board at Panaceutics Inc. She serves as Independent Director of Fulcrum Therapeutics, Inc. since January 2, 2020. She served as Independent Director at Pandion Operations, Inc. (Formerly, Pandion Therapeutics, Inc.) since December 2, 2020. Prior to Repare, she served as Chief Financial Officer of AVROBIO Inc. from September 26, 2017 to 2019, a lentiviral gene therapy company. Ms. Dorton served as Executive Vice President and Chief Financial Officer of Repare Therapeutics Inc. since April 2019 until October 10, 2019, a synthetic lethality and DNA repair-focused oncology company. Ms. Dorton served as Managing Director with Fennebresque & Co. LLC. She has investment banking and Wall Street experience advising corporate clients and their Boards of Directors on mergers and acquisitions and other strategic transactions. She has led the execution of transactions raising in equity and debt, including 25 IPOs and has advised clients on dozens of M&A and other strategic transactions. She is a global financial executive with diverse experience as Chief Financial Officer at several leading biotechnology companies and as a trusted strategic advisor to emerging life science companies through her career in investment banking. Her deep financial expertise includes fundraising strategies, capital structure, financial products, financial analysis and valuation. She has extensive experience in the biopharma industry and finance. Ms. Dorton has significant experience serving as an advisor to numerous companies in life sciences, medical devices and healthcare. She also has substantial international experience having worked in the US and Europe and executed numerous cross-border transactions for US and non-US companies. Ms. Dorton served as the Chief Financial Officer of immatics biotechnologies GmbH since January 8, 2016. She serves as a Partner of Corise Co. She served as Managing Director of Corporate Finance Department at Needham & Company, LLC. She led the life sciences team at Needham & Co. Earlier in her career, she was Investment Banker at Morgan Stanley. She was a Managing Director for Life Sciences in Investment Banking. Her industry focus included the healthcare sector, the communications sector and German corporate clients. She spent many years of her career at Morgan Stanley of which over many years was spent in Morgan Stanley's investment banking. She spent couple of years in a leadership role in Morgan Stanley’s German investment banking business. At Morgan Stanley, she led business groups in the US and in Germany. She was Managing Director at Morgan Stanely. She also served in a senior executive role in Morgan Stanley’s Asset Management Group. Prior to her investment banking career, she practiced law with Sullivan & Cromwell in the areas of mergers and acquisitions and securities law. She served as an attorney in private practice with Sullivan & Cromwell. She serves as Member of Advisory Board at Evatran, LLC. She has been an Independent Director of US Ecology, Inc. since August 20, 2014 and was its Lead Independent Director since May 27, 2015. Ms. Dorton holds B.A. degree in Economics from Duke University, an M.B.A. from George Washington University and a J.D. from the University of Virginia School of Law.
Positions
- Company NameTScan Therapeutics, Inc.Stock CodeTCRXPositionIndependent DirectorColleagues
- GMGavin MacBeathCEO, Principal Financial Officer, Principal Accounting Officer & Director
- SRStephen Richard BiggarIndependent Chair of the Board
- SJStephen J. ElledgeCo-Founder & Chairman of Scientific Advisory Board
- TKTomasz KulaCo-Founder & Member of Advisory Board
- ZZZoran ZdraveskiChief Legal & Strategy Officer and Company Secretary
- AHAnn HargravesChief Human Resources Officer
- KDKatina DortonIndependent Director
- Company NameFulcrum Therapeutics, Inc.Stock CodeFULCPositionIndependent DirectorColleagues
- ACAlexander C. SapirCEO, President & Director
- KHKathryn HavilandIndependent Chair of the Board
- AAAlan A. MussoCFO, Treasurer & Principal Accounting Officer
- CGCurtis G. OltmansChief Legal Officer, Head of External Affairs & Corporate Secretary
- BEBradley E. BernsteinFounder
- MRMichael R. GreenFounder
- JAJames Arthur GeraghtyIndependent Director
- RKRachel K. KingIndependent Director
- Company NamePrelude Therapeutics IncorporatedStock CodePRLDPositionIndependent DirectorsColleagues
- KVKrishna VaddiFounder, CEO & Director
- PAPaul A. FriedmanIndependent Chairman of the Board
- BDBryant David LimCFO, Chief Legal Officer & Corporate Secretary
- PAPeggy A. ScherleChief Scientific Officer
- ACAimee CrombieSenior VP and Head of Strategic Planning & Operations
- MPMadhu PudipeddiSenior Vice President of Technical Operations
- DBDavid BonitaIndependent Director
- VSVictor SandorIndependent Director
- KDKatina DortonIndependent Directors
